T2D who have cardiovascular disease, CKD, or both, the oral formulation of semaglutide GLP-1 receptor agonist, reduces the risk for major adverse cardiovascular events

The ACP developed this guideline based on the best available evidence on the benefits, harms, patient preferences, and economic aspects of pharmacologic treatments for acute episodic migraine.

Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy

Researchers postulated that brain insulin responsiveness may adapt to dietary changes before weight gain, potentially facilitating the development of obesity.

Induction therapy with subcutaneous guselkumab demonstrated significant efficacy in patients with moderately to severely active ulcerative colitis (UC), according to results from the phase 3

For adults, WHO recommends less than 2000 mg/day of sodium (equivalent to less than 5 g/day salt), or just under a teaspoon.

A new dyslipidemia guideline from the American Association of Clinical Endocrinology (AACE)

Romosozumab for 12 months followed by alendronate for 24 months leads to greater improvements in lumbar spine bone density and trabecular bone scores

The US Food and Drug Administration (FDA) has approved suzetrigine 50 mg tablets, a first-in-class nonopioid analgesic for treatment of adults with moderate-to-severe acute pain.